Dasatinib

• Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR Trial Not authorised
  2022-500669-28-00 Phase II 1 country Odense University Hospital
• Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Not authorised
  2024-514411-95-00 Phase II 1 country Wake Forest University Health Sciences
• Clinical trial with dasatinib for the prevention of CAR-T side effects in patients with relapsed or treatment-resistant multiple myeloma und… Pending
  2023-507537-16-00 Phase I/II 1 country Universitaetsklinikum Wuerzburg AöR
• A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos… Recruiting
  2024-511496-14-00 Phase III 7 countries Ascentage Pharma Group Inc.
• Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA… Recruiting
  2022-501866-22-00 Phase I/II 11 countries Princess Maxima Center For Pediatric Oncology
• EVIDENT Recruiting
  2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 Phase III 14 countries Novartis Pharma AG
• A multicenter trial where patients with CML stop medication a second time. Recruiting
  2024-515409-25-00 Phase II 3 countries Region Uppsala
• Safety, tolerance and antiretroviral activity of IMP: a pilot clinical trial in patients with recent HIV-1 infection Ended
  2024-519641-30-00 Phase II 1 country Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
• A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended
  2024-516511-24-00 Phase III/IV 1 country Stichting Radboud universitair medisch centrum
• Safety and Impact of Dasatinib on Inflammation and AIDS virus in People under treatment Ended
  2024-513714-36-01 Phase II 1 country Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol
• AITIK-Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Ended
  2024-515479-36-00 Phase III 1 country Centre Hospitalier Universitaire De Poitiers
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended
  2023-508838-33-00 Phase III 15 countries Novartis Pharma AG
• A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-s… Ended
  2024-514592-17-00 Phase II 1 country Masarykova Univerzita
• VEN-R DASA-IPC 2022-067 Evaluation of DASATINIB monotherapy efficacy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE Halted
  2023-505846-24-00 Phase II 1 country Institut Paoli-Calmettes
• Dasatinib and quercetin, a combination of senolytics to treat fibrotic non-alcoholic fatty liver disease; The TRUTH study Ended
  2024-517593-21-00 Phase II 1 country Amsterdam UMC Stichting
• Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR Trial Ended
  2022-502076-23-00 Phase II 1 country Odense University Hospital
• A Phase II Study of Dasatinib in Children and Adolescents with Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolera… Ended
  2024-510784-36-00 Phase I/II 2 countries Bristol Myers Squibb International Corporation

Showing 1–18 of 18 trials